Clinical Trial Update: Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers [Phase 2]

View source ↗

Summary

A Phase 2 study of Alferon LDO (low-dose oral interferon alfa-N3) in healthy volunteers was completed to assess safety in the context of Severe Acute Respirator…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• Alferon LDO (Low Dose Oral) (interferon alfa-N3)

Snippet

Sponsor: AIM ImmunoTech Inc. | Conditions: Severe Acute Respiratory Syndrome | Phase 2 | Status: COMPLETED